Valuation: Theraclion

Market Cap 48.32M 55.98M 45.34M 41.29M 77.64M 5.35B 78.72M 531M 208M 2.68B 210M 206M 8.92B P/E 2024
-2.66x
P/E 2025 -6.33x
Enterprise Value 56.18M 65.07M 52.7M 48M 90.26M 6.22B 91.51M 618M 242M 3.12B 244M 239M 10.37B EV / Sales 2024
22.5x
EV / Sales 2025 55.4x
Free-Float
54.78%
Yield 2024 *
-
Yield 2025 -
1 day+9.62%
1 week+328.57%
Current month+328.57%
1 month+328.57%
3 months+328.57%
6 months+612.50%
Current year+612.50%
Current year 0.53
Extreme 0.532
2.28
1 year 0.53
Extreme 0.532
2.28
3 years 0
Extreme 0.00017
2.28
5 years 0
Extreme 0.00017
2.28
10 years 0
Extreme 0.00017
2.6
Manager TitleAgeSince
Chief Executive Officer - 24/05/2023
Director of Finance/CFO - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member - 22/06/2021
Director/Board Member - 28/01/2022
Director/Board Member - 29/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
+9.62%+328.57% - - 56.54M
-0.47%-1.43%+19.73%+10.71% 218B
+0.09%-1.04%-3.93%-19.84% 142B
-1.06%+3.04%-18.73%+30.41% 139B
-0.77%+4.30%-50.15%-0.06% 75.11B
-0.86%+1.21%+16.04%+15.26% 52.8B
-0.79%-1.29%-17.14%-16.13% 50.66B
-0.05%+1.70%+24.54%+22.32% 41.95B
-1.07%+0.22%+39.85%+48.34% 40.49B
-1.79%+0.84%-1.40%+2.41% 33.28B
Average +0.41%+1.61%+0.98%+10.38% 88.17B
Weighted average by Cap. -0.35%+1.12%-0.09%+8.45%

Financials

2024 2025
Net sales 830K 962K 779K 709K 1.33M 91.95M 1.35M 9.13M 3.58M 46.07M 3.61M 3.53M 153M 652K 755K 612K 557K 1.05M 72.21M 1.06M 7.17M 2.81M 36.18M 2.84M 2.77M 120M
Net income -5.76M -6.67M -5.4M -4.92M -9.25M -638M -9.38M -63.32M -24.81M -319M -25.04M -24.49M -1.06B -5.69M -6.59M -5.34M -4.86M -9.14M -630M -9.27M -62.58M -24.52M -316M -24.75M -24.21M -1.05B
Net Debt 3.41M 3.95M 3.2M 2.91M 5.48M 378M 5.56M 37.51M 14.7M 189M 14.83M 14.51M 630M 7.85M 9.1M 7.37M 6.71M 12.62M 870M 12.79M 86.35M 33.84M 436M 34.15M 33.41M 1.45B
Logo Theraclion
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of consumables (52.8%); - sale of equipment (28.8%); - provision of after-sales services (18.4%). The vast majority of net sales are earned abroad.
Employees
36

Annual profits - Rate of surprise